Literature DB >> 1129485

Analysis of sites and causes of failures of irradiation in invasive squamous cell carcinoma of the intact uterine cervix.

S Jampolis, E J Andras, G H Fletcher.   

Abstract

An analysis of the records of 916 patients who received radiotherapy for invasive squamous cell carcinoma of the intact uterine cervix from January 1964 through December 1969 revealed that 94% of the central and regional failures will occur within 3 years of treatment. Survival rates were as follows: Stage I, 91%; Stage IIA, 82%; Stage IIB, 65%; Stage IIIA, 54%; and Stage IIIB, 40%. The incidences of central and regional failures in Stages I through III are: Stages I and IIA; central 2% and regional 4.5%; Stage IIB; central 5% and regional 13%; Stage III: central 14% and regional 19%. In stages IIB, IIIA, and IIIB, the main cause of failures, either centrally or in the parametria, is the presence of massive disease.

Entities:  

Mesh:

Year:  1975        PMID: 1129485     DOI: 10.1148/15.3.681

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  10 in total

1.  Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly cisplatin in locally advanced carcinoma cervix.

Authors:  Pragyat Thakur; Rajeev Seam; Manoj Gupta; Manish Gupta
Journal:  Ann Transl Med       Date:  2016-02

2.  Chemoradiotherapy: the new standard care for invasive cervical cancer.

Authors:  P G Rose
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Indication for interstitial brachytherapy in carcinoma of the uterine cervix.

Authors:  P P Kumar; J Taylor; J C Scott; A J Jacobs; J Rojas
Journal:  J Natl Med Assoc       Date:  1984-07       Impact factor: 1.798

4.  The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128.

Authors:  Akila N Viswanathan; Jennifer Moughan; William Small; Charles Levenback; Revathy Iyer; Sharon Hymes; Adam P Dicker; Brigitte Miller; Beth Erickson; David K Gaffney
Journal:  Int J Gynecol Cancer       Date:  2012-01       Impact factor: 3.437

Review 5.  Ovarian and cervical cancer.

Authors:  C Williams
Journal:  BMJ       Date:  1992-06-06

6.  A preliminary results of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer.

Authors:  Young Seok Kim; Seong Soo Shin; Eun Kyung Choi; Jong Hoon Kim; Seung Do Ahn; Sang-wook Lee; Heon-Jin Park; Young-Tak Kim; Jung-Eun Mok; Joo-Hyun Nam
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

7.  High dose remote afterloading radiotherapy for cervix carcinoma in Tanzania: early results.

Authors:  G A Alexander; U K Henschke
Journal:  J Natl Med Assoc       Date:  1981-12       Impact factor: 1.798

8.  The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix.

Authors:  Il Jung Choi; Moon Seok Cha; Eunku Seul Park; Myung Seok Han; Youngmin Choi; Goo Hwa Je; Hyun Ho Kim
Journal:  J Gynecol Oncol       Date:  2008-06-20       Impact factor: 4.401

9.  Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer, stage IIIB in the 2018 FIGO classification.

Authors:  Qingyu Meng; Xiaoliang Liu; Weiping Wang; Xiaorong Hou; Xin Lian; Shuai Sun; Junfang Yan; Zhikai Liu; Zheng Miao; Ke Hu; Fuquan Zhang
Journal:  Radiat Oncol       Date:  2019-12-16       Impact factor: 3.481

10.  Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer.

Authors:  Tae Wook Kong; Suk-Joon Chang; Jiheum Paek; Seung-Chul Yoo; Jong-Hyuck Yoon; Ki-Hong Chang; Mison Chun; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.